Hepatobiliary/Pancreatic Surgery and Abdominal Transplantation Division, University of Southern California, Los Angeles, CA 90033, USA.
Gastroenterol Clin North Am. 2012 Mar;41(1):211-21. doi: 10.1016/j.gtc.2011.12.015.
There have been significant advances made over the years in the areas of critical care, anesthesia, and surgical technique, which have led to improved mortality rates and survival after resection for pancreatic cancer. The standard of care is currently PD or PPPD for pancreatic cancers of the head, uncinate process, or neck and DP for pancreatic cancers of the body or tail. Resections are performed with the goals of negative margins and minimal blood loss, and referral to high-volume centers and surgeons is encouraged. However, 5-year survival rate after curative resection still remains at less than 20%. In an effort to improve survival and extend the limits of resectability, many centers have attempted extended lymphadenectomy and portal venous and even arterial resection and reconstruction. Extended lymphadenectomy has not led to improved survival for these patients. Portal vein resection has increased the number of patients amenable to resection, with equivalent survival rates compared with those of standard resections. Portal vein invasion is thus no longer considered a contraindication to resection at many large centers. Resection and reconstruction of involved arteries have been rarely performed and are currently not considerations for most patients. It is likely that future improvements in survival lie in the realm of adjuvant therapy. As chemotherapeutic and other tumor-directed agents continue to evolve and advance, this will hopefully lead to improved survival for patients undergoing surgical resection for pancreatic cancer.
近年来,在重症监护、麻醉和手术技术领域取得了重大进展,这导致了胰腺癌切除术后死亡率和存活率的提高。目前,对于头部、钩突或颈部的胰腺腺癌采用 PD 或 PPPD,对于体部或尾部的胰腺腺癌采用 DP。手术的目标是阴性切缘和最小的出血量,并鼓励转诊到高容量中心和外科医生。然而,根治性切除术后的 5 年生存率仍低于 20%。为了提高生存率并扩大可切除性的范围,许多中心尝试了扩大淋巴结清扫术以及门静脉甚至动脉切除术和重建术。对于这些患者,扩大淋巴结清扫术并未提高生存率。门静脉切除术增加了可切除的患者数量,与标准切除术的生存率相当。因此,在许多大型中心,门静脉侵犯不再被视为切除的禁忌症。受累动脉的切除和重建很少进行,目前大多数患者都不考虑。未来生存的改善可能在于辅助治疗领域。随着化疗和其他肿瘤靶向药物的不断发展和进步,这有望提高接受胰腺癌手术切除的患者的生存率。